| Course | HCR 350 Introduction to Clinical Research |
|---|---|
| Module | Module 3 |
| Paper type | Drug development topic paper |
| Length | About 466 words, 4 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | BS in Health Care Compliance and Regulations |
| Updated | October 2026 |
Free sample paper for HCR 350 Module 3
The Gateway to Human Testing: The Investigational New Drug Application
Student Name
BS in Health Care Compliance and Regulations, Arizona State University
HCR 350: Introduction to Clinical Research
Instructor Name
Month Day, Year
The Gateway to Human Testing: The Investigational New Drug Application
What the IND Is
An Investigational New Drug application, or IND, is a request to the Food and Drug Administration for permission to give an unapproved drug to people in clinical investigations and to ship it across state lines for that purpose. Its contents are set out in federal regulations: information on the drug's chemistry, manufacturing and controls; results of animal pharmacology and toxicology studies; any previous human experience; and clinical protocols and investigator information for the planned studies (21 C.F.R. § 312.23). Once submitted, the IND goes into effect 30 days later unless the FDA places the study on clinical hold.
Where It Falls in the Process
The IND marks the transition from preclinical research to clinical research. It also continues throughout development: sponsors submit protocol amendments, safety reports and annual reports to the same IND as trials progress.
| Stage | Activity |
|---|---|
| Discovery | Identify and optimize a candidate compound |
| Preclinical | Laboratory and animal studies of safety and activity |
| IND submission | Request to begin human testing |
| Phase 1 to 3 | Clinical trials of safety, dose and effectiveness |
| New Drug Application | Request for approval to market |
| Phase 4 | Postmarketing studies and surveillance |
Why It Matters
Safety. The IND is the FDA's chance to judge whether it is reasonably safe to start human testing, based on animal data and manufacturing quality, and whether the first protocols protect participants. Clinical holds can stop studies that pose unreasonable risk.
Cost and odds. Drug development is long, expensive and uncertain. An analysis of more than 21,000 compounds estimated the probability that a drug entering phase 1 eventually gains approval at roughly 14 percent overall, with much lower rates in oncology (Wong et al., 2019). The estimated average cost per approved new drug, including the cost of failures and the cost of capital, was about $2.6 billion in 2013 dollars (DiMasi et al., 2016). A well-prepared IND does not change those odds, but a poor one can delay development or expose participants to avoidable risk.
Personnel Involved
Sponsor side: regulatory affairs specialists who compile and submit the IND; toxicologists and pharmacologists who provide preclinical data; chemists and manufacturing staff who document drug quality; clinical scientists and medical monitors who write protocols; and safety staff who submit adverse event reports. Investigators and research sites provide qualifications and conduct studies under the IND, with institutional review board approval. FDA side: review divisions with medical, pharmacology, chemistry and statistical reviewers. Compliance professionals help ensure that submissions are complete and that IND obligations, such as safety reporting, are met.
Conclusion
The IND is the gateway between the laboratory and the clinic and remains the regulatory backbone of every trial that follows. Understanding it helps clinical research professionals see why documentation and safety reporting matter at every stage.
References
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33. https://doi.org/10.1016/j.jhealeco.2016.01.012
IND content and format, 21 C.F.R. § 312.23 (2024).
Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics, 20(2), 273-286. https://doi.org/10.1093/biostatistics/kxx069
Reading the HCR 350 Module 3 assignment instructions
Paper 3 lets students pick one topic within the drug development process and asks four things of it: what it is, where it sits in the process, why it matters and who works on it. Those four elements make a ready-made outline. Workable topics include the IND application, first-in-human phase 1 studies, data safety monitoring boards, adverse event reporting, the new drug application and postmarketing surveillance. Choose something narrow enough to explain in depth. Federal regulations and FDA guidance are the primary sources, and peer-reviewed studies are the best way to show why the topic matters in practice.
How this HCR 350 Module 3 example is built
The four parts of the prompt give the sample its shape. It defines the IND by reference to the regulation that lists its contents, places it in the development sequence with a stage-by-stage table and points out that it remains open through every clinical phase. The importance section covers participant safety and uses two well-known studies to show how long the odds and how high the costs of development are. A personnel section identifies who handles the IND at the sponsor, at research sites and inside the FDA, including compliance staff, and a short conclusion ties the topic back to the course. Each section stays brief so the four required elements receive equal weight.
Where the marks sit in the HCR 350 Module 3 rubric
Drug development papers count toward the 300 points for papers and are marked on a Canvas rubric. Typical credit goes to a well-focused topic, a definition grounded in primary sources, accurate placement within the development process, an explanation of importance supported by evidence, a specific account of who is involved and clear APA writing. Deductions usually come from topics that sprawl, from inaccurate descriptions of regulations, from claims of importance without support and from personnel sections that name only generic researchers. Including a simple visual of the development pathway, with your topic highlighted, helps graders see at once that you understand where it fits.
HCR 350 Module 3 help with common mistakes
Use the four elements of the prompt as your headings so nothing is missed. Read the regulation or FDA guidance on your topic yourself instead of relying on summaries. A small table or timeline makes the topic's place in development easy to see. Support any claim about importance with data, such as costs, timelines or success rates. Name specific roles and what each person does. If you are torn between topics, the desk can help you pick the one with the richest sources. End by explaining why a compliance professional in particular should understand your topic, which links the paper to the program's purpose and to the career paths the course introduces. A clear table of stages also helps graders follow your placement of the topic in sequence.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 350 and BS in Health Care Compliance and Regulations sample papers
- HCR 350 Module 1: Paper 1: The NIH Website and the Clinical Research Field
- HCR 350 Module 2: Paper 2: FDA Enforcement and a Disqualified Investigator
- HCR 350 Module 4: Paper 4: Integrating Research Compliance Into the Corporate Compliance Program
- HCR 363 Module 2: Assignment 2: Compliance Risk Assessment Survey
- HCR 264 Module 3: Problem Solving Paper: An OIG Case Analysis
- HCR 262 Module 2: Writing Assignment 2: Professional Misconduct Mock Investigation
HCR 350 Module 3 questions, answered
Where can I find a free HCR 350 Module 3 sample paper?
A full HCR 350 Module 3 sample is on this page: a paper on the Investigational New Drug application in the drug development process.
What is an IND application?
A request to the FDA to begin testing an unapproved drug in people, containing manufacturing, preclinical and protocol information.
When can a trial start after an IND is submitted?
The IND goes into effect 30 days after the FDA receives it unless the FDA places the study on clinical hold.
How likely is a drug in phase 1 to be approved?
One large analysis estimated an overall probability of about 14 percent, lower in oncology.
What topics work for HCR 350 Paper 3?
The IND, phase 1 studies, data safety monitoring boards, adverse event reporting, the new drug application or postmarketing surveillance.